Design Therapeutics Inc. (NASDAQ: DSGN)
$4.55
+0.0650 ( +1.45% ) 213.1K
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
Market Data
Open
$4.55
Previous close
$4.48
Volume
213.1K
Market cap
$257.05M
Day range
$4.28 - $4.71
52 week range
$1.94 - $8.31
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jun 17, 2024 |
4 | Insider transactions | 1 | Jun 17, 2024 |
4 | Insider transactions | 1 | Jun 17, 2024 |
4 | Insider transactions | 1 | Jun 17, 2024 |
4 | Insider transactions | 1 | Jun 17, 2024 |
4 | Insider transactions | 1 | Jun 17, 2024 |
8-k | 8K-related | 11 | Jun 17, 2024 |
8-k | 8K-related | 13 | May 08, 2024 |
10-q | Quarterly Reports | 58 | May 08, 2024 |
def | Proxies and info statements | 5 | Apr 25, 2024 |